CBPartners’ Commercial Planning practice will never simply deliver results – facts and findings are taken to the next level for meaningful insights, comparative revelation, and strategic guidance.
Showing 5 of 15 posts
September 22, 2021 | Blogs
In part two of this series about non-traditional players in the healthcare space, CBPartners dives into one company’s (Walmart) recently established partnership with a traditional pharmaceutical company (Novo Nordisk) to investigate the larger ramifications of these new entrants for key stakeholders – patients, the pharmaceutical industry, and their traditional competition.
August 30, 2021 | Blogs
Verily recently announced its first major acquisition, a software platform known as SignalPath. The acquisition would fold SignalPath into Baseline, Verily’s clinical research platform.
October 20, 2020 | Blogs
Pharma and biotech companies should be prepared to make long-term investments in capability building, market development, and evidence generation to maximize the value of digital companions.
September 17, 2020 | Blogs
Hitting the Mark: Lessons Learned From Blockbuster Drugs That Missed or Exceeded Analyst Expectations
Pharmaceutical products can both exceed and fall short of blockbuster sales expectations by considerable margins which can be a result of a number of reasons. Some of these include the value of first-to-market dynamics, supporting real-world evidence to gain a competitive edge, and continual investment in trials for follow-on indications to improve life cycle management.
September 8, 2020 | Blogs
How Do Companies Spend the Revenue Generated from Blockbuster Drugs? A Closer Look at Vertex and Gilead
Blockbuster drugs can generate billions of dollars for pharmaceutical manufacturers, but what can be learned from the investment strategies that GILEAD and VERTEX pursued from the revenue that they generated from SOVALDI and ORKAMBI respectively?